Mesenchymal stromal cells in renal transplantation: opportunities and challenges
- PMID: 26853275
- DOI: 10.1038/nrneph.2016.7
Mesenchymal stromal cells in renal transplantation: opportunities and challenges
Abstract
Lifelong immunosuppressive therapy is essential to prevent allograft rejection in transplant recipients. Long-term, nonspecific immunosuppression can, however, result in life-threatening complications and fail to prevent chronic graft rejection. Bone marrow (BM)-derived multipotent mesenchymal stromal cells (MSCs) have emerged as a potential candidate for cell-based therapy to modulate the immune response in organ transplantation. These cells can repair tissue after injury and downregulate many of the effector functions of immune cells that participate in the alloimmune response, converting them into regulatory cells. The findings of preclinical and initial clinical studies support the potential tolerance-inducing effects of MSCs and highlight the unanticipated complexity of MSC therapy in kidney transplantation. In animal models of transplantation MSCs promote donor-specific tolerance through the generation of regulatory T cells and antigen-presenting cells. In some settings, however, MSCs can acquire proinflammatory properties and contribute to allograft dysfunction. The available data from small clinical studies suggest that cell infusion is safe and well tolerated by kidney transplant recipients. Ongoing and future trials will provide evidence regarding the long-term safety of MSC therapy and determine the optimum cell source (either autologous or allogeneic) and infusion protocol to achieve operational tolerance in kidney transplant recipients. These studies will also provide additional evidence regarding the risks and benefits of MSC infusion and will hopefully offer definitive answers to the important questions of when, where, how many and which types of MSCs should be infused to fully exploit their immunomodulatory, pro-tolerogenic and tissue-repairing properties.
Similar articles
-
Marrow Mesenchymal Stem Cells Effectively Reduce Histologic Changes in a Rat Model of Chronic Renal Allograft Rejection.Transplant Proc. 2017 Nov;49(9):2194-2203. doi: 10.1016/j.transproceed.2017.09.038. Transplant Proc. 2017. PMID: 29149982
-
Mesenchymal stromal cells for tolerance induction in organ transplantation.Hum Immunol. 2018 May;79(5):304-313. doi: 10.1016/j.humimm.2017.12.008. Epub 2017 Dec 27. Hum Immunol. 2018. PMID: 29288697 Review.
-
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation.Transpl Int. 2013 Sep;26(9):867-78. doi: 10.1111/tri.12132. Epub 2013 Jun 6. Transpl Int. 2013. PMID: 23738760 Clinical Trial.
-
Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.J Transl Med. 2015 Nov 4;13:344. doi: 10.1186/s12967-015-0700-0. J Transl Med. 2015. PMID: 26537851 Free PMC article. Clinical Trial.
-
Mesenchymal stromal cells to promote solid organ transplantation tolerance.Curr Opin Organ Transplant. 2013 Feb;18(1):51-8. doi: 10.1097/MOT.0b013e32835c5016. Curr Opin Organ Transplant. 2013. PMID: 23254705 Review.
Cited by
-
Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease.Stem Cell Res Ther. 2019 Nov 28;10(1):354. doi: 10.1186/s13287-019-1478-4. Stem Cell Res Ther. 2019. PMID: 31779707 Free PMC article.
-
Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology.J Am Soc Nephrol. 2018 Feb;29(2):362-375. doi: 10.1681/ASN.2017070781. Epub 2017 Nov 30. J Am Soc Nephrol. 2018. PMID: 29191959 Free PMC article. Review.
-
Infusing Mesenchymal Stromal Cells into Porcine Kidneys during Normothermic Machine Perfusion: Intact MSCs Can Be Traced and Localised to Glomeruli.Int J Mol Sci. 2019 Jul 23;20(14):3607. doi: 10.3390/ijms20143607. Int J Mol Sci. 2019. PMID: 31340593 Free PMC article.
-
Chronic Infections: A Possible Scenario for Autophagy and Senescence Cross-Talk.Cells. 2018 Oct 10;7(10):162. doi: 10.3390/cells7100162. Cells. 2018. PMID: 30308990 Free PMC article. Review.
-
Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration.Commun Biol. 2022 Aug 25;5(1):867. doi: 10.1038/s42003-022-03833-8. Commun Biol. 2022. PMID: 36008710 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical